Selected article for: "plaque reduction and standard plaque assay"

Author: Elste, James; Kaltenbach, Dominik; Patel, Vraj R.; Nguyen, Max T.; Sharthiya, Harsh; Tandon, Ritesh; Mehta, Satish K.; Volin, Michael V.; Fornaro, Michele; Tiwari, Vaibhav; Desai, Umesh R.
Title: Inhibition of Human Cytomegalovirus Entry into Host Cells through A Pleiotropic Small Molecule
  • Document date: 2020_2_29
  • ID: 031ro01b_24
    Snippet: The effect observed on the expression of important viral genes led to the prediction that SPGG possibly does not just function as a heparan sulfate competitor. We reasoned that SPGG may possibly bind to proteins involved in viral spread too. To test this hypothesis at a morphological level, rather than at a molecular level, we studied the phenomenon of viral spread using a plaque reduction assay. In this assay, we used β-galactosidase-expressing.....
    Document: The effect observed on the expression of important viral genes led to the prediction that SPGG possibly does not just function as a heparan sulfate competitor. We reasoned that SPGG may possibly bind to proteins involved in viral spread too. To test this hypothesis at a morphological level, rather than at a molecular level, we studied the phenomenon of viral spread using a plaque reduction assay. In this assay, we used β-galactosidase-expressing reporter HCMV strain (RC256 from ATCC), which upon expression of β-galactosidase and x-gal staining in the infected cells showed blue foci. Plaque reduction assay have been considered the gold standard for antiviral susceptibility testing [68] .

    Search related documents:
    Co phrase search for related documents
    • antiviral susceptibility and HCMV strain: 1
    • antiviral susceptibility and heparan sulfate competitor: 1
    • antiviral susceptibility and heparan sulfate competitor function: 1
    • antiviral susceptibility and hypothesis test: 1
    • antiviral susceptibility and β galactosidase: 1
    • antiviral susceptibility and infected cell: 1
    • antiviral susceptibility and molecular level: 1
    • antiviral susceptibility and molecular level morphological level hypothesis test: 1
    • antiviral susceptibility and morphological level: 1
    • antiviral susceptibility and morphological level hypothesis test: 1
    • antiviral susceptibility and plaque reduction: 1
    • antiviral susceptibility and plaque reduction assay: 1
    • antiviral susceptibility and plaque reduction assay viral spread: 1
    • antiviral susceptibility and plaque reduction assay viral spread phenomenon: 1
    • antiviral susceptibility and possibly heparan sulfate competitor function: 1
    • antiviral susceptibility and reduction assay: 1
    • antiviral susceptibility and SPGG possibly heparan sulfate competitor function: 1
    • antiviral susceptibility and sulfate competitor: 1
    • antiviral susceptibility and viral gene: 1, 2